Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 7;40(1):156.
doi: 10.1186/s13046-021-01966-y.

José Baselga M.D., Ph.D. (1959-2021) leading cancer researcher and oncologist

Moshe Elkabets  1 , Giovanni Blandino  2
Affiliations

José Baselga M.D., Ph.D. (1959-2021) leading cancer researcher and oncologist

Moshe Elkabets et al. J Exp Clin Cancer Res. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests

Similar articles

  • ESMO pays tribute to Professor José Baselga.
    Peters S, Tabernero J, Cervantes A, Banerjee S, Giuliani R, Lordick F. Peters S, et al. Immunooncol Technol. 2021 Apr 27;9:100027. doi: 10.1016/j.iotech.2021.100027. eCollection 2021 Mar. Immunooncol Technol. 2021. PMID: 35756863 Free PMC article. No abstract available.
  • José Baselga 1959-2021.
    Scaltriti M. Scaltriti M. Nat Cancer. 2021 May;2(5):479-480. doi: 10.1038/s43018-021-00209-5. Nat Cancer. 2021. PMID: 35122018 No abstract available.
  • ESMO pays tribute to Professor José Baselga.
    Peters S, Tabernero J, Cervantes A, Banerjee S, Giuliani R, Lordick F. Peters S, et al. Ann Oncol. 2021 Jul;32(7):823-824. doi: 10.1016/j.annonc.2021.04.001. Epub 2021 Apr 27. Ann Oncol. 2021. PMID: 34090547 No abstract available.
  • José Baselga (1959-2021).
    Castel P, Toska E, Vasan N, Cocco E, Scaltriti M. Castel P, et al. Cancer Cell. 2021 May 10;39(5):581-582. doi: 10.1016/j.ccell.2021.04.003. Epub 2021 Apr 29. Cancer Cell. 2021. PMID: 33930314 No abstract available.
  • The role of the radiation oncologist in quality and patient safety: A proposal of indicators and metrics.
    Calvo FA, Chera BS, Zubizarreta E, Scalliet P, Prasad RR, Quarneti A, Akbarov K, Abdel-Wahab M. Calvo FA, et al. Crit Rev Oncol Hematol. 2020 Oct;154:103045. doi: 10.1016/j.critrevonc.2020.103045. Epub 2020 Jul 18. Crit Rev Oncol Hematol. 2020. PMID: 32769020 Review.
See all similar articles

References

    1. Fan Z, Baselga J, Masui H, Mendelsohn J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-Diamminedichloroplatinum on well established A431 cell Xenografts. Cancer Res. 1993;53:4637-42. - PubMed
    1. Baselga J, Norton L, Masui H, Pandiella A, Coplan K, Miller WH, et al. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst. 1993;85:1327–1333. doi: 10.1093/jnci/85.16.1327. - DOI - PubMed
    1. Rusch V, Baselga J, Cordon-Cardo C, Orazem J, Aman M, Hoda S, et al. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung1. 1993. - PubMed
    1. Baselga J, Norton L, Albanell J, Kim Y-M, Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptinâ¢) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer Xenografts. Cancer Res. 1998;58(13):2825-31. - PubMed
    1. Baselga J, Seidman AD, Peter Rosen P, Norton L. HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications. Oncology. 1997:43–8 [cited 2021 Apr 18]. Available from: https://europepmc.org/article/med/9110342. - PubMed

LinkOut - more resources